Shakeel Modak Advances in Neuroblastoma Research Congress 2016

Abstracts this author is presenting:

• ¹⁸F-Meta Fluorobenzyl Guanidine (MFBG) Positron Emission Tomography(PET) imaging in patients with Neuroblastoma and other Neuroendocrine Malignancies — Poster Session 2 with wine & cheese
• Phase II study of the combination of bevacizumab plus irinotecan and temozolomide for relapsed or refractory neuroblastoma — Poster Session 1 with wine & cheese
• Phase I study of anti-G_D2 humanized 3F8 (hu3F8) monoclonal antibody (MAb) plus GM-CSF: High dosing and major responses in patients with resistant high-risk neuroblastoma (HR-NB) — Parallel 4 Novel Therapies and Immunotherapy
• ¹²⁴I-hu3F8 radioimmuno-positron emission tomography (PET) in patients with neuroblastoma and other GD2-positive malignancies: preliminary results on biodistribution, pharmacokinetics and tumor targeting — Poster Session 2 with wine & cheese
• Discordance in ¹²³I-MIBG (MIBG) and ¹⁸FDG positron emitting tomography (PET) scans after multimodality therapy for high-risk neuroblastoma: clinical implications — Parallel 8 Clinical Imaging, Risk Factors and Response
• Event-free survival (EFS) and overall survival (OS) of MYCN-amplified stage 2/3 neuroblastoma with or without autologous stem-cell transplantation (ASCT) — Poster Session 1 with wine & cheese